TLX 117
Alternative Names: TLX-117Latest Information Update: 28 Nov 2023
At a glance
- Originator Tulex Pharmaceuticals
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for clinical-Phase-Unknown development in Cardiovascular-disorders in USA
- 15 Oct 2020 TLX 117 is available for licensing as of 15 Oct 2020. https://www.tulexpharm.com/
- 15 Oct 2020 Clinical trials in Cardiovascular disorders in USA (Tulex Pharmaceuticals pipeline, October 2020)